TABLE 6.
Neutralization activity of anti-S MAbs against SARS pseudovirus (Tor2)
| Epitope | MAb | Inhibition of ACE2 bindinga | ND50 (μg/ml) |
|---|---|---|---|
| S1-NT (linear) | 114E3 | − | >50 |
| 115H2 | ND | >50 | |
| 116F8 | ND | >50 | |
| S1-NT-I (Conf) | 103D1 | − | >50 |
| 109B4 | ND | >50 | |
| 113G3 | ND | >50 | |
| S1-NT-II (Conf) | 120D9 | − | 24.78 |
| S1-NT-II (Conf/linear) | 109D7 | ND | >50 |
| 120B11 | ND | >50 | |
| 121E9 | ND | >50 | |
| S1-NT-III (Conf) | 106B3 | − | 25.64 |
| 111E3 | ND | 33.56 | |
| 112D5 | ND | 46.82 | |
| 112H6 | ND | 27.98 | |
| S1-NT-IV (Conf) | 101E7 | − | >50 |
| 112F9 | ND | >50 | |
| S1-NT-V (Conf) | 104F10 | ND | >50 |
| S1-RBD-I (Conf) | 102A12 | + | 0.02 |
| 106C5 | + | 0.20 | |
| 112B7 | + | 0.05 | |
| S1-RBD-II (Conf) | 103D3 | − | 0.01 |
| 119F8 | − | 1.56 | |
| S1-RBD-III (Conf) | 106C7 | − | 0.20 |
| 106H2 | + | 0.10 | |
| 109G7 | + | 2.25 | |
| 121D7 | + | 0.01 | |
| S1-CT (linear) | 101F10 | ND | >50 |
| 103F2 | − | >50 | |
| 104D4 | ND | >50 | |
| 111A7 | ND | >50 | |
| 114G5 | ND | >50 | |
| 121B8 | ND | >50 | |
| S2 (linear) | 114F7 | − | >50 |
| 102D7 | ND | >50 | |
| 119F6 | ND | >50 | |
| 108G2 | ND | >50 | |
| S2 (Conf) | 117F7 | ND | >50 |
| S2 (Conf/linear) | 102B11 | − | >50 |
a
ND, not done; + and −, inhibition and noninhibition of receptor binding, respectively.